Cipla
Cipla Limited is a global pharmaceutical company based in India focused on the development, manufacturing, and distribution of generic and branded pharmaceutical products. The company produces therapeutic formulations across respiratory, cardiovascular, anti-retroviral, central nervous system, and anti-infective segments, alongside active pharmaceutical ingredients. Principal revenues are generated through branded generic prescription sales, over-the-counter health products, and bulk active ingredient manufacturing contracts. Cipla serves healthcare providers, retail pharmacy chains, hospitals, and public health organizations across India, North America, South Africa, and international markets. The enterprise holds a market-leading global position in respiratory therapies and anti-retroviral HIV treatments. Cipla Limited is headquartered in Mumbai, India, and its common shares are listed on the BSE Limited and the National Stock Exchange of India.
15 of the funds FundTelligence covers report a position in Cipla.
- Legal name
- CIPLA Ltd
- Sector
- Health Care
- Country
- India
- Funds holding it
- 15
Funds holding Cipla
- Franklin India Fund — Franklin Templeton · 2.54 % (full portfolio disclosed, September 2026)
- Storebrand Emerging Markets — Storebrand · 0.1 % (full portfolio disclosed, October 2026)
- Mercer Passive Emerging Markets Equity Fund — Mercer · 0.09 % (full portfolio disclosed, December 2025)
- Danske Invest Global Emerging Markets Index Restricted — Danske Invest · 0.09 % (full portfolio disclosed, July 2026)
- Lannebo Emerging Markets — Lannebo · 0.08 % (full portfolio disclosed, June 2026)
- Storebrand Indeks Nye Markeder — Storebrand · 0.07 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.07 % (full portfolio disclosed, October 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.07 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 15 funds holding it.